News for Schrödinger, Inc. (SDGR)

Schrödinger, Inc. (NASDAQ:SDGR) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds. Morgan Stanley assumed coverage on the company’s stock with an “Equalweight” rating and a price objective of $28.00, down from the prior target of $31.00, as reported by The Fly. As per the firm’s analyst, Schrödinger, Inc. (NASDAQ:SDGR) saw […]

NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Schrödinger, Inc. (”œSchrödinger” or the ”œ

Schrödinger, Inc. (NASDAQ:SDGR) is one of the top 10 healthcare AI stocks to buy according to hedge funds. Schrödinger, Inc. (NASDAQ:SDGR) announced that its investigational drug SGR-1505 has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of adults with Waldenström macroglobulinemia who have not responded to at least […]

PR NewswireNEW YORK, July 2, 2025 NEW YORK, July 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Schrödinger, Inc.

SHANGHAI, June 30, 2025 /PRNewswire/ -- On June 30th, Beijing time, Unisound, a pioneer in the industrialization of AI technologies in China and a portfolio company of Qiming Venture Partners, has successfully debuted on the Hong Kong Stock Exchange. Unisound (SEHK:9678) was issued at HK$205.00 per share, with a market capitalization of HK$14.545 billion.

NEW YORK, June 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Schrödinger, Inc. (”œSchrödinger” or the ”œ

[url="]Schrödinger[/url], Inc. (Nasdaq: SDGR) today announced that SGR-1505, its clinical stage MALT1 inhibitor, was designated as a Fast Track product by the

Schrödinger (SDGR) receives FDA Fast Track designation for SGR-1505, targeting Waldenström macroglobulinemia. SGR-1505 shows promise in clinical trial

NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Schrödinger, Inc. (”œSchrödinger” or the ”œ

PR NewswireNEW YORK, June 22, 2025 NEW YORK, June 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Schrödinger, In

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Schrödinger, Inc. (”œSchrödinger” or the ”œ

Schrödinger, Inc. (Nasdaq: SDGR) today reported that on June 13, 2025, the company granted restricted stock units (RSUs) with respect to 10,290 shares of the

Schrödinger, Inc. (SDGR) grants restricted stock units (RSUs) for 10,290 shares to five new employees. The RSUs are part of the 2021 Inducement Equity

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Schrödinger, Inc. (”œSchrödinger” or the ”œ

Schrödinger (SDGR) stock fell after Phase 1 trial data for SGR-1505 its experimental drug for B-cell malignancies. Read more here.

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Schrödinger, Inc. (”œSchrödinger” or the ”œC

PR NewswireNEW YORK, June 7, 2025 NEW YORK, June 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Schrödinger, Inc.

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Schrödinger, Inc. (”œSchrödinger” or the ”œ

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Schrödinger, Inc. (”œSchrödinger” or the ”œ